GlassScriptPhysician profile
Philip A Matorin
NPI 1407858384
$8,672.70
in general payments reported to CMS, 2019-2025
13 companies · $764 in 2025
The $764 reported for 2025 was more than what a typical Otolaryngology provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $180 · 2020: $159 · 2021: $449 · 2022: $355 · 2023: $606 · 2024: $6,160 · 2025: $764.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Debt Forgiveness: $5,872 · Food and Beverage: $1,657.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Debt Forgiveness | $5,872.41 |
| Food and Beverage | $1,657.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Photonicare INC | $5,872.41 | 2024 | Otosight Middle Ear Scope |
| Glaxosmithkline, LLC. | $700.88 | 2021-2025 | Nucala |
| Acclarent, INC | $642.95 | 2019-2024 | Acclarent Aera |
| Inspire Medical Systems, INC. | $415.83 | 2023-2025 | Inspire |
| Optinose US, INC. | $306.99 | 2019-2025 | |
| Genzyme Corporation | $275.33 | 2021-2025 | |
| Aerin Medical INC. | $131.08 | 2025 | |
| Integra Lifesciences Corporation | $124.52 | 2022-2025 | Trudi Probe, Inspira Air, Acclarent Aera |
| Regeneron Healthcare Solutions, INC. | $99.23 | 2022-2025 | Dupixent |
| Ars Pharmaceuticals Operations, INC. | $43.96 | 2025 | Neffy |
| Stryker Corporation | $24.90 | 2019 | |
| Intersect Ent, INC. | $17.45 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $17.17 | 2025 | Tezspire |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Philip Matorin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.